Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

1

Anti-BCMA CAR-T therapy is increasingly used for relapsed/refractory multiple myeloma, necessitating effective bridging therapy prior to treatment.
2

Experts recommend bridging therapy to reduce tumor burden and maintain patient performance while minimizing treatment-related toxicity.
3

Talquetamab, a bispecific T-cell engager, shows promise as an effective bridging therapy option before anti-BCMA CAR-T treatment.
4

Real-world data indicate that effective bridging therapy can improve outcomes and minimize adverse events in multiple myeloma patients.
5

A panel of experts aims to provide guidance on optimal bridging therapy selection to standardize care in the rapidly evolving field of multiple myeloma.

Bone Marrow Transplantation

by Leo Rasche, Maria Theresa Krauth, Hermine Agis, Christoph Renner, Irene Strassl, Raphael Teipel, Vladan Vučinić, Katja Weisel, Wolfgang Willenbacher, Marc S. Raab
May 13, 2026

1